Sharon Pearce
Community Health · Dolgeville, NYNPI 1558736355
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 126 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 22 manufacturers, the largest accounting for just 22.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,114 and has fallen 98.5% since, to $17 in 2025. Among community health clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 126 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$618
- AbbVie$451
- Novo Nordisk$406
- GSK$367
- Boehringer Ingelheim$162
- Merck$144
- plus $613 from 16 others
What the payments were for
- Food & beverage$2,761100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 28 | $618 |
| AbbVie | 13 | $451 |
| Novo Nordisk | 13 | $406 |
| GSK | 24 | $367 |
| Boehringer Ingelheim | 10 | $162 |
| Merck | 5 | $144 |
| Pfizer | 4 | $82 |
| Amarin Pharma, Inc. | 4 | $76 |
| Novartis | 4 | $73 |
| Exact Sciences | 3 | $56 |
| Phathom Pharmaceuticals, Inc. | 3 | $52 |
| Lilly USA, LLC | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 3 | $48 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $33 |
| Astellas Pharma US Inc | 1 | $22 |
| Amgen | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $18 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Abbott | 1 | $17 |
| Johnson & Johnson | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,761 in reported general payments places this provider in the 90th percentile of 21 community health providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $59,085 |
| JardianceEmpagliflozin | 18 | $31,379 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $26,841 |
| EliquisApixaban | 19 | $22,375 |
| OxycontinOxycodone Hcl | 18 | $16,008 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 29 | $1,814 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 48 | $1,489 |
| Oxycodone Hcl | 54 | $1,008 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $665 |
| Bisoprolol-HydrochlorothiazideBisoprolol/Hydrochlorothiazide | 11 | $589 |
| Atorvastatin Calcium | 74 | $562 |
| Roflumilast | 13 | $548 |
| Gabapentin | 32 | $495 |
| Levothyroxine Sodium | 51 | $470 |
| Omeprazole | 41 | $392 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $406 | $59,08545 claims |
| Boehringer IngelheimJardiance | $162 | $31,37918 claims |
| GSKTrelegy Ellipta | $367 | $26,84127 claims |
| PfizerEliquis | $82 | $22,37519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 21 community health providers in New York.
Other community health in Dolgeville
- Edwin TorresNew York$76K
- Scott RosmanBinghamton$13K
- Danielle MejiasBinghamton$1K
- Megan CoghlanSyracuse$529
- Desiree DarrisawNew York$506
- Stacey RosmanBinghamton$457
- Mallory FurnissWest Amherst$442
- Dayle BowerVestal$416
- Dawn LawyerNew York$305
- Richard CrooksonBrooklyn$289
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.